IMA NASDAQ
ImageneBio Inc
1W: -2.5%
1M: -7.3%
3M: -23.3%
YTD: -31.9%
1Y: -46.0%
3Y: -91.3%
5Y: -97.0%
$4.60
+0.02 (+0.43%)
Weekly Expected Move ±3.9%
$4
$4
$5
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.51
Bullish
8 bullish
6 neutral
0 bearish
Articles (7d)
14
Daily Sentiment (7 Days)
Articles (100)
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna
Uriage Presents New Scientific Advances in Triple Barrier Science at EADV Congress 2026 in Vienna
PearlMatrix® P-15 Peptide Enhanced Bone Graft Receives Medicare New Technology Add-on Payment (NTAP), Helping Hospitals Accelerate Lumbar Fusion
Nanoscope Therapeutics Announces PMDA Acceptance and Priority Review of New Drug Application for MOGENRY® in Japan for the Treatment of Inherited Retinal Dystrophies
EpiSign Launches METRIC 5-base, Enabling Comprehensive Episignature Analysis Across Genome-Sequencing Platforms
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Rongtao Medical Maps 22 Ultrasound Parts and Repair Providers to Four Service Routes
EClinCloud's eCOA Platform Reaches 177 Countries and Regions as Multi-Regional Trials Drive Electronic Outcome Capture
VEMERIX Launches Patented Single-Use Ultrasound Guidance Puncture Kit With Probe-Matched Customization
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
Roche launches newborn screening test for three severe genetic conditions
Roche launches newborn screening test for three severe genetic conditions
Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer
MAYPHARM Unveils HYALMASS AQUATOX, a Next-Generation Multi-Active Skin Solution for the Global Aesthetic Market
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
PB125® Enhanced Vascular Function in Older Adults and Preserved Vascular Function During Disuse in Human Clinical Study
Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance
Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership
Glytec Receives FDA Breakthrough Device Designation for Glucommander Pediatrics, an Insulin Management Technology for Hospitalized Newborns and Infants
Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
NET Recovery Granted FDA Breakthrough Device Designation for Stimulant Use Disorder, Where No Drug is FDA-Approved or Medical Device FDA-Cleared
Angel Yeast's Angeopro™ Yeast Protein Achieves Dual International Certifications
TENA Answers Women's Most-Searched Pelvic Floor Questions For Healthy Aging Month
Dama Health Earns the NurseApproved Seal for Dama Assist, Its AI-Powered Clinical Platform for Hormone Health and Menopause Care
First patient treated with Leqembi® (lecanemab) in Sweden
First patient treated with Leqembi® (lecanemab) in Sweden
Introducing the Next-Generation LightStim for Wrinkles and LightStim for Acne
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Le Groupe Menarini et NewAmsterdam Pharma obtiennent l'autorisation de la Commission européenne pour Ubeslo® (obicetrapib en monothérapie) et Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
Hedia Secures Regulatory Approval to Expand Digital Diabetes Care to Pediatric Patients
Hedia erhält behördliche Genehmigung zur Ausweitung der digitalen Diabetesversorgung auf pädiatrische Patienten
Hedia obtiene la aprobación para ampliar la atención digital de la diabetes a pacientes pediátricos
Hedia obtient l'autorisation réglementaire d'étendre sa prise en charge numérique du diabète aux patients pédiatriques
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Menarini Group und NewAmsterdam Pharma erhalten von der Europäischen Kommission die Zulassung für Ubeslo® (Obicetrapib als Monotherapie) und Evlarco® (Fixkombination aus Obicetrapib und Ezetimib)
Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia
Koning Health Announces Australian Regulatory Approval for Koning Breast CT System
mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
Pulsenmore Expands Its Fertility Platform into the UK
Neutrogena® Launches New Sunscreen Technology with Cloud-Tech™, Combining Next-Generation Sun Protection, Skincare Benefits, and a Weightless Feel
Akeso's EGFR/TROP2 Bispecific ADC AK158D1 Granted NMPA Phase I Clearance for Advanced Solid Tumors, Marking Its Fourth Clinical-Stage ADC Candidate
Aptitude Announces FDA 510(k) Clearance of Next-Generation Metrix® COVID Test
KELLS AI Dental Scan Registered as Class B Medical Device with Singapore HSA
DifGen Pharmaceuticals LLC Announces U.S. FDA Approval of Epinephrine Injection USP, 1 mg/mL, Single-Dose Vials
TS Cyanergy's CE2 Engine Monitoring Platform Earns ABS Approval
Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks
Leqembi® Pen subcutaneous formulation approved in Japan
Leqembi® Pen subcutaneous formulation approved in Japan
ZBeats Receives FDA Clearance for ZBPro Diagnostic v2.0, Supporting ECG Analysis Up to 14 Days
Natus Launches Locally Manufactured Nicolet EDX System in China
Zipalertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in First-Line EGFR Exon 20 Insertion-Positive NSCLC
Eight-Year ADAURA Update Shows Sustained Overall Survival Benefit With Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
Intuitive announces expanded indication for da Vinci SP in Europe
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
Glenmark launches RYALTRIS® in Brazil
ADAMA Secures First EU Registration for Innovative Ferrabait® Molluscicide
AFT Pharmaceuticals partners with Mark Cuban Cost Plus Marketplace to bring the new non-opioid pain medication, Combogesic® to the U.S.
Bright Uro expands Board Leadership with addition of two Medtech and Urology Industry Veterans
egnite Unveils Major CardioCare® Platform Improvements with a New UI that Enables Even Faster and Easier Access to Critical CV Data
Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring
CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities
Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP
Argo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026
HR HealthCare Launches Liv™ Pre-lubricated Intermittent Catheter for Women
ClinHope Officially Establishes Hong Kong Branch to Strengthen Asia-Pacific Market Presence
APsystems Achieves Key Safety Milestone with APstorage 261L UL 9540A Test Success
Himplant® Receives ANMAT Approval, Paving the Way for Launch in Argentina
Simcere Zaiming signe un accord de licence exclusif avec Roche pour le développement mondial du SIM0660
PixCell Medical Expands into Canada Through Partnership with Inter Medico Following Health Canada Class III Licence for HemoScreen
Bayesian Health's FDA-Cleared Continuous AI Sepsis Monitor Approved for Medicare New Technology Add-on Payment (NTAP)
Alteogen Enters Option and License Agreement with Novartis for Development and Commercialization of Hybrozyme™-Enabled Subcutaneous Products
Simcere Zaiming schließt exklusive Lizenzvereinbarung mit Roche über die weltweite Entwicklung von SIM0660
Simcere Zaiming sluit exclusieve licentieovereenkomst met Roche voor wereldwijde ontwikkeling van SIM0660
Medibyt Receives FDA 510(k) Clearance for CPETWise, Advancing Cardiopulmonary Exercise Test Analysis and Interpretation
BioViva Announces U.S. Patent for Klotho Gene Therapy Targeting Age-Related Cognitive Decline
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
Canada's Drug Agency issues final positive recommendation supporting public reimbursement of Leqembi®
Ultra Violette Becomes First Brand in the US to Launch a Sunscreen Containing Newly FDA-Approved Filter Bemotrizinol
/C O R R E C C I O N -- Bridge to Life, Ltd./
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Au Royaume-Uni, le NICE publie des recommandations préconisant le financement systématique par le NHS du système de perfusion hypothermique oxygénée VitaSmart™ de Bridge to Life
/C O R R E C T I O N -- Bridge to Life, Ltd./
VEMERIX Report Reveals the True Cost of Mesotherapy Consumables and the 2026 Rules Reshaping Injector Sourcing
HUM Nutrition Launches Stack & Sculpt™, a Peptide-Powered Creatine for Toning
Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA
Cytrellis Launches ellacor® Micro-Coring® Technology for Full-Body Skin Resurfacing in Australia
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
GC Biopharma's Hunter Syndrome Treatment 'Hunterase' Receives Drug Approval in India and Taiwan
3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline